Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)16.81bn
- Net income in DKK3.09bn
- Incorporated1950
- Employees5.57k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
More ▼
Mergers & acquisitions
| Acquired company | LUN:CPH since announced | Transaction value |
|---|---|---|
| Abide Therapeutics Inc | -13.35% | 400.00m |
Data delayed at least 15 minutes, as of Dec 11 2019 14:15 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia Ltd | 414.86m | -3.15bn | 26.15bn | 636.00 | -- | 11.68 | -- | 63.04 | -3.51 | -3.51 | 0.4622 | 2.49 | 0.0457 | -- | 15.81 | -- | -34.75 | -- | -37.36 | -- | -- | -- | -760.78 | -- | -- | -- | 0.6436 | -- | -61.65 | -- | -2,607.90 | -- | -- | -- |
| MorphoSys AG | 531.82m | -717.82m | 29.64bn | 405.00 | -- | 8.87 | -- | 55.73 | -3.04 | -3.04 | 2.25 | 13.99 | 0.1271 | 12.66 | 4.51 | 216,295.10 | -17.15 | -7.94 | -18.72 | -8.67 | 95.14 | -- | -134.97 | -48.05 | 7.79 | -- | 0.0891 | -- | 14.45 | -0.3924 | 19.55 | -- | -15.02 | -- |
| Swedish Orphan Biovitrum AB (publ) | 8.46bn | 1.80bn | 32.37bn | 1.28k | 17.21 | 2.85 | 12.08 | 3.83 | 8.84 | 8.84 | 41.45 | 53.34 | 0.4863 | 2.11 | 6.83 | 13,224,940.00 | 10.35 | 8.78 | 13.24 | 11.13 | 75.22 | 69.64 | 21.28 | 15.60 | 0.9236 | 18.06 | 0.3664 | 0.00 | 40.36 | 33.24 | 110.50 | -- | 7.10 | -- |
| Hikma Pharmaceuticals Plc | 14.35bn | 2.43bn | 41.70bn | 8.41k | 17.16 | 3.37 | 13.11 | 2.91 | 1.13 | 1.13 | 6.68 | 5.77 | 0.6128 | 1.83 | 3.51 | 192,474.70 | 10.39 | 0.5943 | 15.08 | 0.802 | 52.16 | 53.22 | 16.95 | 1.02 | 0.8459 | 11.71 | 0.2737 | 518.67 | 7.23 | 8.75 | 131.61 | 5.87 | 13.13 | 13.12 |
| Orion Corp | 7.76bn | 1.56bn | 42.38bn | 3.24k | 27.11 | 7.95 | 21.71 | 5.46 | 1.49 | 1.48 | 7.39 | 5.07 | 1.03 | 1.81 | 6.07 | 329,359.50 | 20.68 | 20.74 | 26.59 | 26.36 | 60.93 | 60.23 | 20.12 | 21.21 | 1.85 | 98.67 | 0.0114 | 92.04 | -5.43 | -0.5909 | -9.90 | -0.8685 | -1.84 | 3.71 |
| argenx SE | 402.24m | -749.31m | 44.68bn | 105.00 | -- | -- | -- | 111.09 | -2.69 | -2.69 | 1.46 | -- | -- | -- | -- | 512,590.50 | -- | -16.05 | -- | -18.23 | -- | -- | -186.28 | -170.29 | -- | -- | -- | -- | -41.01 | 51.66 | -137.36 | -- | 60.11 | -- |
| Ipsen SA | 18.80bn | 3.03bn | 49.55bn | 5.72k | 16.25 | 3.32 | 11.93 | 2.63 | 4.87 | 4.94 | 30.16 | 23.85 | 0.6213 | 2.46 | 4.94 | 439,664.50 | 9.98 | 10.50 | 15.05 | 14.26 | 81.13 | 79.29 | 16.06 | 13.73 | 0.6134 | 44.12 | 0.3623 | 29.24 | 16.73 | 12.87 | 43.52 | 22.30 | 35.72 | 4.56 |
| H. Lundbeck A/S | 16.81bn | 3.09bn | 50.78bn | 5.57k | 16.39 | 3.53 | 11.88 | 3.02 | 15.55 | 15.55 | 84.59 | 72.28 | 0.7329 | 1.84 | 4.42 | 3,268,715.00 | 13.48 | 1.72 | 20.09 | 2.56 | 80.45 | 73.94 | 18.39 | 2.40 | 1.12 | -- | 0.0458 | 235.62 | 5.12 | 3.49 | 48.89 | 35.51 | -14.21 | 34.07 |
| DiaSorin SpA | -747.35bn | -747.35bn | 51.01bn | 1.95k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.48 | -- | 18.05 | -- | 68.02 | -- | 21.12 | -- | -- | -- | 35.10 | 4.97 | 9.00 | 13.05 | 13.75 | 10.46 | 10.35 |
| Croda International Plc | 12.40bn | 2.08bn | 55.38bn | 4.58k | 26.84 | 7.24 | 20.92 | 4.47 | 1.81 | 1.81 | 10.75 | 6.69 | 0.7503 | 3.10 | 5.78 | 305,414.80 | 12.61 | 14.43 | 15.30 | 17.59 | 36.94 | 35.98 | 16.81 | 16.49 | 0.9314 | 28.38 | 0.4382 | 82.11 | 1.01 | 5.19 | 3.92 | 6.07 | 17.53 | 5.43 |
| Qiagen NV | 10.22bn | -171.39m | 64.82bn | 5.20k | -- | 3.80 | 47.39 | 6.35 | -0.1156 | -0.1156 | 5.91 | 9.82 | 0.2904 | 3.20 | 4.45 | 276,022.30 | -0.4872 | 2.17 | -0.6026 | 2.38 | 65.41 | 65.39 | -1.68 | 7.23 | 2.18 | 5.62 | 0.4166 | -- | 5.95 | 2.90 | 1,032.96 | 22.48 | 4.90 | -- |
| Eurofins Scientific SE | 31.43bn | 2.31bn | 65.67bn | 42.55k | 29.19 | 3.28 | 13.36 | 2.09 | 16.93 | 7.89 | 229.90 | 150.71 | 0.6171 | 53.15 | 5.12 | 95,974.53 | 5.23 | 5.94 | 7.10 | 7.73 | 19.36 | 18.79 | 8.48 | 9.34 | 0.7423 | 6.93 | 0.5642 | 16.65 | 27.25 | 25.27 | 17.06 | 25.74 | 29.63 | 19.14 |
| BioMerieux SA | 18.89bn | 1.97bn | 73.07bn | 11.09k | 37.21 | 4.73 | 21.71 | 3.87 | 2.22 | 2.22 | 21.34 | 17.45 | 0.7488 | 2.59 | 5.37 | 227,798.80 | 7.71 | 6.46 | 9.89 | 8.51 | 54.53 | 51.97 | 10.29 | 8.78 | 1.06 | 12.39 | 0.2402 | 21.76 | 5.82 | 8.80 | 7.81 | 9.33 | 11.55 | 0.9808 |
Data as of Dec 11 2019. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK
6.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 30 Sep 2019 | 4.12m | 2.07% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 2.54m | 1.27% |
| The Vanguard Group, Inc.as of 31 Oct 2019 | 1.70m | 0.86% |
| BlackRock Fund Advisorsas of 05 Dec 2019 | 1.38m | 0.70% |
| APG Asset Management NVas of 31 Mar 2019 | 881.34k | 0.44% |
| Dimensional Fund Advisors LPas of 08 Dec 2019 | 843.48k | 0.42% |
| SEB Investment Management ABas of 31 Oct 2019 | 632.04k | 0.32% |
| Nordea Investment Management AB (Denmark)as of 28 Oct 2019 | 597.67k | 0.30% |
| Bessemer Investment Management LLCas of 31 Jul 2019 | 568.88k | 0.29% |
| Danske Bank A/S (Investment Management)as of 09 Dec 2019 | 527.36k | 0.27% |
More ▼
Data from 31 Dec 2018 - 09 Dec 2019Source: FactSet Research Systems Inc.
